MBX Biosciences Taps Biopharma Dealmaker Karen Basbaum as CBO
Event summary
- Karen Basbaum joins MBX Biosciences as Chief Business Officer on March 10, 2026.
- Basbaum brings 20+ years of biopharma business development experience, including roles at Poseida Therapeutics and Amylin Pharmaceuticals.
- Previously led $10B+ in strategic partnerships and corporate transactions, including Poseida's $1.5B sale to Roche.
- MBX Biosciences focuses on precision peptide therapies for endocrine and metabolic disorders.
- Company's pipeline includes canvuparatide (Phase 3 prep), MBX 4291 (Phase 1), and imapextide (Phase 2).
The big picture
MBX Biosciences' appointment of Karen Basbaum as CBO signals an aggressive push for strategic partnerships and transactions, following a pattern seen in biopharma companies preparing for late-stage clinical advancements. Basbaum's experience in structuring billion-dollar deals suggests MBX may be positioning itself for significant collaborations or acquisitions to accelerate its pipeline. The move comes as precision peptide therapies gain traction in treating endocrine and metabolic disorders, a market with substantial unmet medical needs and large commercial potential.
What we're watching
- Deal Execution
- Whether Basbaum can replicate her track record of high-value partnerships at MBX Biosciences.
- Pipeline Acceleration
- The pace at which MBX advances its Phase 3-ready canvuparatide and other pipeline candidates.
- Strategic Transactions
- How MBX leverages Basbaum's M&A expertise to potentially attract larger pharmaceutical partners.